National Institutes of Health to Grant Exclusive License for Immunotoxins with In-Vivo T Cell Suppressant Activity

Summary

The National Institutes of Health (NIH) is considering granting an exclusive worldwide license to Sandoz Pharma Ltd. for the use of immunotoxins with in-vivo T cell suppressant activity, as described in U.S. Patent 5,167,956 and other patent applications.